Exelixis, Inc. (EXEL): Cash & Equivalents
$482.49M
As of 2026-01-02, Fiscal 2025
$281.45M
As of 2026-07-03
-1.3%
3-year compound annual growth
+8.6%
5-year compound annual growth
+13.0%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $482.49M | +122.0% | 2026-02-10, Balance as of period end |
| 2025-01-03, Fiscal 2024 | $217.37M | -17.3% | 2026-02-10, Balance as of period end |
| 2023-12-29 | $262.99M | -47.5% | 2025-02-11, Balance as of period end |
| 2022-12-30 | $501.19M | -22.6% | 2024-02-06, Balance as of period end |
| 2021-12-31 | $647.17M | +102.7% | 2023-02-07, Balance as of period end |
| 2021-01-01, Fiscal 2020 | $319.22M | +19.8% | 2022-02-18, Balance as of period end |
| 2020-01-03, Fiscal 2019 | $266.50M | -15.3% | 2021-02-11, Balance as of period end |
| 2018-12-28 | $314.77M | +71.9% | 2020-02-25, Balance as of period end |
| 2017-12-29 | $183.16M | +20.8% | 2020-02-25, Balance as of period end |
| 2016-12-31 | $151.69M | n/a | 2017-02-27, Balance as of period end |
| 2016-12-30 | $151.69M | +7.1% | 2019-02-22, Balance as of period end |
| 2016-01-01, Fiscal 2015 | $141.63M | n/a | 2018-02-26, Balance as of period end |
| 2015-12-31 | $141.63M | +76.2% | 2017-02-27, Balance as of period end |
| 2014-12-31 | $80.39M | -22.7% | 2017-02-27, Balance as of period end |
| 2013-12-31 | $103.98M | -38.9% | 2017-02-27, Balance as of period end |
| 2012-12-31 | $170.07M | +129.0% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $74.26M | -23.8% | 2014-02-20, Balance as of period end |
| 2010-12-31 | $97.44M | +12.3% | 2013-02-21, Balance as of period end |
| 2009-12-31 | $86.80M | n/a | 2012-02-22, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $839.00M | +26.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $2.60B | +34.7% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $133.82M | +15.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Novavax Inc (NVAX) | 2025-12-31 | $240.63M | -54.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗